Diego Muñoz-Torrero graduated in Pharmacy at the University of Barcelona (1989), where he received the PhD degree (Medicinal Chemistry) in 1994 under the supervision of Prof. Pelayo Camps. For 2 years (Jan 1996 to Dec 1997) he was a postdoctoral researcher at the Institut für Organische Chemie of the Georg-August Universität (Göttingen, Germany), under the supervision of Prof. Reinhard Brückner.
In 2001 he was appointed Associate Professor of Organic and Medicinal Chemistry at the Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona (UB) and since July 2022 he is Full Professor at the same department.
He was Vice-Dean of Research of the Faculty of Pharmacy and Food Sciences (UB) from November 2009 until March 2018. He is currently Head of the Laboratory of Pharmaceutical Chemistry of his faculty and member of the Governing Board of the Institute of Biomedicine of the UB (IBUB-Drug and Target Discovery) since its founding in 2007.
He is a member of the Spanish Society of Medicinal Chemistry (SEQT) and the Spanish Royal Society of Chemistry (RSEQ), Organic Chemistry Division.
He has authored 110 papers, 10 patents, and 7 book chapters, and guest-edited 18 special issues in medicinal chemistry journals and 9 E-books.
He currently serves as the Editor-in-Chief of the Medicinal Chemistry Section of the MDPI journal Molecules and belongs to the editorial advisory board of several medicinal chemistry journals.
Dr. Elsa Martínez
Dr. Ana Mallo-Abreu
Dr. Elsa Martínez
is a post-doctoral researcher who has recently joined Dr. Diego Muñoz-Torrero’s lab as part of a collaboration with La Fundació Bosch i Gimpera and the Vall d’Hebron Institute of Oncology (VHIO). After completing her MSc in Industrial Chemistry and Introduction to Chemical Research in 2014 at the Autonomous University of Barcelona, she moved to the University of Birmingham (UK), where she undertook her PhD under the supervision of Dr. Paul Davies from 2014 to 2018. Her project consisted of the development of a general strategy to construct complex imidazolyl heterocycles through a gold-catalysed annulation process. Following that, she worked as a Teaching Fellow in the Collaborative Teaching Laboratory at the University of Birmingham.
is a 3rd year PhD student, graduated in Pharmacy by the University of Barcelona. After having spent two months of research training in Dr. Diego Muñoz-Torrero’s lab as an undergraduated student, she performed an Erasmus+ placement at Trinity Biomedical Sciences Institute (TBSI) in 2019, under the supervision of Prof. John Gilmer. After that, she obtained a collaboration scholarship to work in Dr. Diego Muñoz-Torrero’s lab, in a project devoted to the synthesis of novel multitarget anti-Alzheimer drug candidates. Then she participated in the 2019 LLAV 00017 project (AGAUR and FEDER) “Dual acting compounds for the treatment of neurodegenerative diseases”. Later, she obtained a predoctoral fellowship from Fundació Pedro i Pons to undertake a three-months placement in QPS Austria GmbH, where she performed in vitro studies of multitarget compounds. Currently, she is developing her PhD thesis in Dr. Diego Muñoz-Torrero’s group with the FPU predoctoral scholarship from the Ministerio de Universidades.
is a second-year PhD student at the group of Diego Muñoz-Torrero in the University of Barcelona. During his master degree in the Philippines, he worked on the synthesis and derivatization of small molecules having a Michael acceptor moiety and tested them against various disease indications, namely as anti-inflammatory, anti-cancer and antimicrobial agents. He is one of the recipients of a three-year scholarship granted by the Philippine – Department of Science and Technology (DOST) in 2021 to pursue PhD studies. Currently his research interest focuses on the development of novel drug candidates with innovative mechanisms for the treatment of neurodegenerative diseases.
is a second-year PhD student at the group of Diego Muñoz-Torrero in the University of Barcelona. She has been working for some months in 2019 and beginning of 2020 in the group of Dr. Diego Muñoz-Torrero. She has collaborated in a project aimed at the synthesis of novel compounds that hit multiple targets involved in the pathogenesis of Alzheimer’s disease. Within this project, she has also performed the evaluation of the inhibitory activity of the synthesized compounds against the aggregation of β-amyloid peptide in Escherichia coli cells. Finally, she did his final degree work in the same group, studying the evolution of scientific interest in multi-targeted drugs and the different targets of Alzheimer’s disease. Currently, she is developing her PhD thesis with the FPU predoctoral scholarship from the Ministerio de Universidades.
is graduated in Chemistry from the Autonomous University of Madrid with a master in Drug Discovery. After graduation, he joined Spanish National Cancer Research Center (CNIO, Madrid), where he worked in the Medicinal Chemistry section as a synthetic chemist, gaining experience in the early stages of the drug discovery process. He collabored in the synthesis and optimization of compounds, either classical small-molecule inhibitors or protein degraders. He started his PhD. under the supervision of Dr. Diego Muñoz-Torrero and Dr. Santiago Vázquez in September 2022. The topic of his thesis will focus on the rational design, synthesis and evaluation of novel drug candidates with innovative mechanisms of action for the treatment of neurodegenerative diseases and neuropathic pain.
is an undergraduate Pharmacy student at University of Barcelona who has been working in the group of Dr. Diego Muñoz-Torrero since summer 2021. He is collaborating in a project with the aim of developing new antimalarial agents.
Design and synthesis of novel aminoquinoline chemotherapeutic agents
Human African Trypanosomiasis (HAT), caused by Trypanosoma brucei gambiense or T. brucei rhodesiense, and malaria, caused by Plasmodium species, are…+ info
Design and synthesis of novel disease-modifying anti-Alzheimer compounds
Healthy ageing is becoming increasingly threatened by a number of age-related neurodegenerative diseases, including Alzheimer’s disease (AD). AD causes loss…+ info
Unveiling the multitarget anti-Alzheimer drug discovery landscape: A bibliometric analysis
Sampietro, A.; Pérez-Areales, F. J.; Martínez, P.; Arce, E. M.; Galdeano, C.; Muñoz-Torrero, D. Pharmaceuticals 2022, 15, 545+ info
Discovery and in vivo proof of concept of a highly potent dual inhibitor of soluble epoxide hydrolase and acetylcholinesterase for the treatment of Alzheimer’s disease
Codony, S.; Pont, C.; Griñán-Ferré, C.; Di Pede-Mattatelli, A.; Calvó-Tusell, C.; Feixas, F.; Osuna, S.; Jarné-Ferrer, J.; Naldi, M.; Bartolini,…+ info
From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects
Pont, C.; Ginex, T.; Griñán-Ferré, C.; Scheiner, M.; Mattellone, A.; Martínez, N.; Arce, E. M.; Soriano-Fernández, Y.; Naldi, M.; De…+ info
Synthesis of compounds with innovative mechanisms against neurodegenerative diseases and neuropathic pain. Sept 2021-Aug 2024. Ministerio de Ciencia e Innovación / Agencia Estatal de Investigación / FEDER (PID2020-118127RB-I00). 225,000 €. PI: Diego Muñoz-Torrero and Santiago Vázquez
Novel dual acting compounds for the treatment of neurodegenerative disorders. 2020-2021. Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) / FEDER (2019 LLAV 00017). 20,000 €. PI: Diego Muñoz-Torrero
Synthesis of compounds with innovative mechanisms against neurodegenerative diseases. 2018-2020. Ministerio de Economía y Competitividad (SAF2017-82771-R). 100,000 €. PI: Diego Muñoz-Torrero and Santiago Vázquez
Development of novel routes of synthesis of intermediates and optimization of organic synthesis processes of intermediates and active pharmaceutical ingredients. 2018. Medichem S.A. (FBG309659). 20,000 €. PI: Diego Muñoz-Torrero
Medicinal chemistry and pharmacology of neurodegenerative diseases. 2017-2020. Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (2017SGR106). 20,000 €. PI: Diego Muñoz-Torrero
Exploration of novel targes and multitarget strategies for the design of compounds against infective and prevalent diseases. 2015-2017. Ministerio de Economía y Competitividad (SAF2014-57094-R). 180,000 €. PI: F. Javier Luque and Diego Muñoz-Torrero
Collaboration between the University of Barcelona and Genoma España for the development of anti-Alzheimer disease-modifying compounds and actions for the development, industrial exploitation and commercialization of the patent ES201000016. 2010-2013. Fundación para el desarrollo de la investigación en genómica y proteómica (Genoma España) (FBG 306351). 105,213 €. PI: Diego Muñoz-Torrero
Compounds for use in the treatment of hyperproliferative disorders
García Palmer, H.; Puig, I.; Tabernero, J.; Galdeano, C.; Muñoz-Torrero, D.; Barril, X.; Ruiz, S.
Date of priority: 2021
Main institution: Fundació Privada Institut d’Investigació Oncològica de Vall d’Hebron (VHIO) / Universitat de Barcelona / Fundació Institució Catalana de Recerca i Estudis Avançats (ICREA)
Companies that are exploiting the patent: Oniria Therapeutics S.L.
Compounds for the treatment of malaria
Fernàndez Busquets, X.; Biosca, A.; Bouzón, I.; Muñoz-Torrero, D.
Date of priority: 2021
Main institution: Fundació Institut de Bioenginyeria de Catalunya (IBEC) / Fundació ISGlobal – Institut de Salut Global Barcelona / Universitat de Barcelona
Multitarget compounds for the treatment of Alzheimer’s disease
Muñoz-Torrero, D.; Vázquez, S.; Pont, C.; Codony, S
Patent WO 2020/193448 A1
Date of priority: 2019
Main institution: University of Barcelona
Multi-target drug compounds for the treatment of neurodegenerative disorders
Muñoz-Torrero, D.; Ferrer, I.; Sola, I.; Aso, E.
Patent WO2014206877 A1
Date of priority: 2014
Main institution: University of Barcelona / IDIBELL
Beta-amyloid-directed multitarget compounds for the treatment of Alzheimer’s disease
Muñoz-Torrero, D.; Inestrosa, N.C.; Viayna, E.; Sola, I.; Vázquez, S.
Patent WO2013EP59683; US 9,238,626 B2
Date of priority: 2013
Main institution: Universitat de Barcelona / Pontificia Universidad Católica de Chile
F. Javier Luque, Department of Nutrition, Food Sciences and Gastronomy, Faculty of Pharmacy and Food Sciences, University of Barcelona (computational studies)
Raimon Sabaté, Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona (amyloid aggregation studies in E. coli)
M. Victòria Clos / Belén Pérez, Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona (in vitro, ex vivo and in vivo pharmacology and PAMPA-BBB)
Manuela Bartolini, Department of Pharmacy and Biotechnology, University of Bologna (cholinesterase inhibition studies, in vitro amyloid aggregation)
Vincenza Andrisano / Angela De Simone, Department for Life Quality Studies, University of Bologna (BACE-1 inhibition studies)
Manuela Prokesch, QPS Neuropharmacology, Grambach, Austria (in vitro, cell-based and in vivo studies)
Laboratory of Medicinal Chemistry
Faculty of Pharmacy and Food Sciences
University of Barcelona
Tel. 93 4024533
Scopus Author ID: 6604023002
Researcher ID: K-9787-2014